Blocking BTLA–HVEM interactions in preclinical settings has been shown to partially restore NK cell cytotoxicity and increase tumor clearance, suggesting that BTLA may be a key checkpoint in restraining NK cell-mediated immunity [46,71]. The gene discussed is TNFRSF14; the disease is neoplasm.